ICON HOLDINGS UNLIMITED COMPANY

Icon Holdings Unlimited Company (ICON) is a global leader in clinical research and development services, helping biopharma, medical-device and health-technology sponsors bring innovative therapies to patients faster. Drawing on deep scientific expertise and cutting-edge technology, ICON offers a full spectrum of solutions - from early-phase clinical and bioanalytical support to specialised cardiac-safety monitoring, real-world patient-centric recruitment, and precision-medicine laboratory services.

The company's portfolio includes bespoke "blended" solutions that tackle unique sponsor challenges, an AI-enhanced voice-of-the-customer platform called EngageAI, and a comprehensive suite of outcome-measure tools that focus on evidence-based results that matter to patients. ICON also provides dedicated biotech services such as due-diligence, asset valuation and market-access consulting, alongside specialist cardiac safety studies, specialty laboratory capabilities and robust site-and-patient solutions.

Through regular whitepapers, webinars and industry surveys, ICON shares best-practice guidance on topics ranging from AI in software-as-a-medical-device to the implementation of ICH GCP E6(R3). Its pragmatic, award-winning approach positions ICON as a trusted partner for organisations seeking to navigate the complexities of modern drug and device development.